Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.52 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

uluru inc (ULUR) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/19/14 - $1.35
52 Week Low
04/20/15 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ULURU INC (ULUR)

Related News

No related news articles were found.

uluru inc (ULUR) Related Businessweek News

No Related Businessweek News Found

uluru inc (ULUR) Details

ULURU Inc., a specialty pharmaceutical company, develops and commercializes a range of wound care and mucoadhesive film products in the United States and internationally. It develops its products based on patented Nanoflex and OraDisc drug delivery technologies. The company’s products include Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and abrasions, as well as non-healing surgical wounds, trauma, and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. It also offers Aphthasol for the treatment of canker sores, as well as for use in the prevention of formation of ulcers; OraDisc A for the treatment of oral conditions, which rely upon the use of medications formulated as gels and pastes that are applied to lesions in the mouth; and OraDisc B, a mucoadhesive disc product that is use for the treatment and management of oral pain. The company’s OraDisc products are also used for various dental applications. ULURU Inc. is based in Addison, Texas.

7 Employees
Last Reported Date: 05/20/15

uluru inc (ULUR) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $335.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $200.0K
Vice President of Polymer Drug Delivery
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2014.

uluru inc (ULUR) Key Developments

Uluru Inc. Appoints Bradley J. Sacks to the Board of Directors

ULURU Inc. announced that in response to the nomination of two directors by a major stockholder, the company's Board of Directors has agreed to expand the Board of Directors from four to five members immediately and to six directors at the 2015 Annual Meeting of Stockholders. The Board appointed Bradley J. Sacks to fill the initial vacancy on the company's Board of Directors. Mr. Sacks is an investor and advisor, and has been since 2009 the managing member of Centric Capital Ventures LLC. In addition, the Board of Directors will be recommending the appointment of Robert F. Goldrich to fill the sixth seat on the board at the 2015 Annual Meeting of Stockholders.

ULURU Inc. Announces Interim Pharmacoeconomic Data

ULURU Inc. announced interim results of a pharmacoeconomic evaluation being conducted in Europe. The pharmacoeconomic data has two components. The first component is the costs associated with using Altrazeal compared to both a conventional dry wound healing dressings and advanced moist wound dressings for an identical duration of treatment. The second component compares the cost of using Altrazeal to conventional dry wound healing dressings and advanced moist wound dressings for the duration of treatment through wound closure. Currently, the CE Mark in Europe allows for Altrazeal to remain in place for up to 14 days. Clinical practice in this patient population resulted in Altrazeal being changed on average every 9 days. Despite the unit cost of Altrazeal being higher than competitive dressings, the reduction in dressing changes and the associated personnel costs makes Altrazeal markedly economically preferable to conventional gauze dressings and advanced moist wound dressings including hydrocolloids, alginates, and foam dressings. The interim data comparing Altrazeal with conventional dry wound healing and advanced moist wound dressings on similar wounds for the duration of treatment through wound closure includes 43 patients treated with Altrazeal. In the patient population evaluated, compared to patients in available data bases using conventional treatments, Altrazeal demonstrated acceleration in wound healing. When combined with the lower treatment cost associated with using Altrazeal, this generates a significant reduction in the cost to complete wound closure. The cost comparison using Altrazeal under the assumption of an identical 50 day period compared with alternative approaches.

ULURU Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

ULURU Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were $294,648 compared to $101,980 a year ago, The increase of $193,000 in revenues is attributable to an increase in Altrazeal product sales primarily reflecting a significant shipment to Middle East distributors, and reflects the revised pricing resulting from the recently announced acquisition of Altrazeal Trading GmbH. Operating loss was $632,668 compared to $773,445 a year ago. Loss before income taxes was $738,273 compared to $868,291 a year ago. Net loss allocable to common shareholders was $738,273 or $0.03 basic and diluted per share compared to $868,291 or $0.04 basic and diluted per share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULUR:US $0.52 USD 0.00

ULUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $151.31 USD +0.195
Smith & Nephew PLC 1,135 GBp +11.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ULUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.1x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ULURU INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at